导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -18.79% | 4304/4773 |
| 近一周 | -3.25% | 4660/5465 |
| 近一月 | -1.74% | 1265/5421 |
| 近一季 | -8.04% | 3079/5231 |
| 近半年 | -23.72% | 4656/4920 |
| 近一年 | -11.56% | 3496/4394 |
| 近两年 | 29.82% | 2287/2954 |
| 近三年 | 1.34% | 1909/2253 |
| 成立以来 | -34.46% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.43% 1798/4961 |
-17.94% 4800/5312 |
- - |
- - |
| 2025 | 29.80% 1379/4813 |
6.61% 608/3635 |
-2.53% 3359/4076 |
16.58% 2634/4524 |
7.15% 315/4813 |
| 2024 | 2.78% 1956/3463 |
1.05% 902/2808 |
-6.44% 1949/3014 |
10.53% 2617/3129 |
-1.65% 1780/3463 |
| 2023 | -4.48% 679/2656 |
2.74% 1307/2280 |
-5.25% 1407/2385 |
2.63% 224/2515 |
-4.39% 1004/2655 |
| 2022 | -20.26% 949/2207 |
-8.45% 282/1919 |
1.43% 1477/2016 |
-14.99% 1185/2113 |
1.02% 1407/2208 |
| 2021 | 47.53% 10/1822 |
17.53% 1/1255 |
9.52% 547/1330 |
22.06% 37/1466 |
-6.09% 1532/1822 |
| 2020 | 9.87% 839/1250 |
-9.17% 661/1028 |
5.81% 874/1067 |
6.32% 854/1164 |
7.53% 707/1184 |
| 2019 | 2.72% 805/1092 |
19.06% 632/754 |
-9.59% 669/804 |
-9.65% 834/850 |
5.62% 698/918 |
| 2018 | -37.31% 597/834 |
- - |
- - |
- - |
-27.47% 677/691 |
| 2017 | 12.40% 280/714 |
- - |
- - |
- - |
- - |
| 2016 | -10.07% 275/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 国联国证钢铁行业指数(LOF)A VS. 长安沪深300非周期A(740101) |